Hematopoietic stem cell (CD34 positive, autologous) (HSC (CD34+))

CD34+ hematopoietic stem cells are rare multipotent progenitors found in adult bone marrow and mobilized peripheral blood, identified by surface expression of the CD34 antigen—a transmembrane sialomucin glycoprotein involved in cell adhesion and migration[2][4][8]. These cells serve as the founding population for all circulating blood and immune cells in humans, supporting lifelong hematopoiesis[8]. The autologous designation indicates that the stem cells are collected from and given back to the same patient, a common practice in hematopoietic stem cell transplantation for various cancers and blood disorders. CD34 is not a therapeutic target itself, but a marker used to isolate, enumerate, and characterize hematopoietic stem/progenitor cells for research, clinical transplantation, or regenerative therapies[4][5][8]. CD34 expression and abundance are critical biomarkers for graft potency in stem cell transplants and for evaluating marrow function; however, the CD34 molecule itself is not a drug or receptor target in the conventional sense[4][5][8]. Autologous stem cells have reduced risk of immunological rejection or graft-versus-host disease; their main therapeutic risks stem from poor reconstitution potential or contamination with diseased cells in malignancies. "Autologous hematopoietic CD34+ stem cells" is not a single molecular target (like a receptor, enzyme, or transporter), but rather a population of human cells defined by cell surface phenotype; thus, it is not considered a "therapeutic target" under standard drug target definitions, and should be flagged as is_incorrect: true in that sense[4][8].

Other names

Autologous hematopoietic CD34+ stem cellCD34+ hematopoietic stem cellCD34-positive HSCHematopoietic stem/progenitor cell (CD34+)

Mobilization (drugs like G-CSF, plerixafor increase numbers of circulating CD34+ HSCs for collection and transplant)